Nanotechnology – a robust tool for fighting the challenges of drug resistance in non-small cell lung cancer

• Filip Gorachinov,
• Fatima Mraiche,
• Diala Alhaj Moustafa,
• Ola Hishari,
• Yomna Ismail,
• Jensa Joseph,
• Maja Simonoska Crcarevska,
• Marija Glavas Dodov,
• Nikola Geskovski and
• Katerina Goracinova

Beilstein J. Nanotechnol. 2023, 14, 240–261, doi:10.3762/bjnano.14.23

• intracellular internalization, and bring advantages over conventional nanocarriers. Keywords: co-delivery nanoparticles; combinatorial therapy; EGFR TKI resistance; non-small cell lung cancer (NSCLC); overcoming and preventing resistance; Introduction Among the malignant diseases, lung cancer takes the lead

• various multiple anti-tumor targets [20][22][90]. Surface-engineered nanoparticles for lung tumor targeting and co-delivery of combinatorial therapy Simultaneous delivery of combinatorial inhibitors with the goal of targeting multiple constituents within a single pathway or different oncogenic pathways in

• task limited by extracellular and intracellular challenges. Combinatorial therapy further complicates the right-time, right-place co-delivery of siRNA with other active ingredients due to the differences in the physicochemical properties, delivery, and stability problems. The nanoparticle core for

The impact of molecular tumor profiling on the design strategies for targeting myeloid leukemia and EGFR/CD44-positive solid tumors

• Nikola Geskovski,
• Nadica Matevska-Geshkovska,
• Simona Dimchevska Sazdovska,
• Marija Glavas Dodov,
• Kristina Mladenovska and
• Katerina Goracinova

Beilstein J. Nanotechnol. 2021, 12, 375–401, doi:10.3762/bjnano.12.31

• alternatives using NDDSs [1]. Literature data points to combinatorial therapy, coadministration, and codelivery of agents by nanomedicines as a successful approach to bypass signaling inhibition, combat anticancer drug resistance, and increase the efficacy of the clinical treatment. Further advances in

• mechanisms and increasing the overall therapeutic effect. Still, it is challenging to coordinate pharmacokinetics, biodistribution, and intracellular concentration profiles of individual drugs with different physiochemical and biological properties [57][58]. Hence, current clinical combinatorial therapy